The Neuroprotective and Antinociceptive effect of Antidiabetic 3-(2-chlorophenyl)-4-imino-5-phenyl-2-(2-methoxyphenyl)-2H,3H,5H-[1,2,5]thiadiazolidin-1-oxide (CIPMTO) in Streptozotocin-induced diabetic neuropathic pain in rats: primary proof of concept

Abstract

In this study the neuroprotective and antinociceptive effect of a newly synthesized chemical moiety, a thiazolidin derivative, 3-(2-chlorophenyl)-4-imino-5-phenyl-2-(2-methoxyphenyl)-2H,3H,5H-[1,2,5]thiadiazolidin-1-oxide (CIPMTO) in streptozotocin (STZ) induced diabetic neuropathic pain is examined in rat therapeutic model. Multiple behavior and biochemical parameters were assessed on the therapeutic model to understand the role of CIPMTO. In this study, male Wistar rats (220-250 g) were used (7 groups, one group was not given any kind of chemical treatment (normal control). All other 6 groups were given a dose of STZ. Carboxymethylcellulose (CMC) was used as a vehicle for CIPMTO in this study. Out of those 6 groups, 1 group was given no other treatment (negative control), 1 group was given CMC only (Vehicle control), 3 groups were treated with different doses of CIPMTO, and 1 group was treated with pregabalin (positive control). Thereafter multiple behavioral studies and biochemical testing were carried out. CIPMTO is found to attenuate the STZ induced behavioral and biochemical changes in a dose-dependent manner (5, 10, and 15 mg/kg) as compared to that of the pregabalin-treated group. CIPMTO also reduced STZ-induced diabetic NP, which is attributable to its neuroprotective potential via pharmacological activities such as free radical scavenging, anti-lipid peroxidation, and inhibition of intracellular calcium accumulation. The current study shows that CIPMTO has neuroprotective and antinociceptive properties, as well as the ability to reduce neuropathic pain. Though further research and testing could be conducted for establishing the fact.